Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC DRUGS OF ABUSE TEST GUIDANCE RECOMMENDS CONSUMER STUDY WITH POST-TESTING SURVEY; DRAFT DOCUMENT SLATED FOR FDA PANEL REVIEW SEPT. 25

This article was originally published in The Gray Sheet

Executive Summary

An FDA guidance on over-the-counter test kits for drugs of abuse is scheduled for review by the agency's Clinical Chemistry and Clinical Toxicology Devices Panel on Sept. 25 in Bethesda, Maryland.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT008728

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel